Dr. Assi is an Assistant Professor of Medicine at Chobanian and Avedisian School of Medicine (BUSM) and a medical oncologist in the section of Hematology/Oncology at Boston Medical Center (BMC). He graduated from medical school at the American University of Beirut in Lebanon and completed his residency in Internal Medicine at Albany Medical Center in Albany, NY. He further completed his training in Hematology/Oncology at University of Oklahoma Health Sciences Center, while also receiving a Master's degree in Clinical and Translational Sciences. His work is focuses on gastrointestinal malignancies, with special focus on neuroendocrine tumors (NETs). His aim is to establish himself as an independent clinical investigator, with a focus on delivering novel therapeutics in NETs. His current research focuses on studying prognostic biomarkers in pancreatic NETs.
Diversity, Equity, Inclusion and Accessibility
I am deeply committed to Boston Medical Center's mission of "exceptional care without exception". For me, this means providing care and the utmost empathy to all patients, regardless of race, ethnicity, religious views, sexual orientation, socioeconomic status, or spoken language. Recognizing that we all have our implicit biases which we can always improve on, I aim to continue to be mindful during my interactions with my surrounding, including other faculty, staff, and patients.
This tab shows grant data from BMC Sponsored Research. It includes:
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data from BU Sponsored Research. It includes:
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data that did not automatically get imported into Profiles
from BU or BMC sources.
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data from the Boston VA. We are only showing grant title, and only for people in the role of PI.
RYZ101-30109/27/2023 - 09/26/2026 (PI)
RayzeBio, Inc.
A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects with Carcinoid Syndrome09/21/2022 - 09/20/2025 (PI)
Crinetics Pharmaceuticals, Inc
|
Yr
|
Title
|
Project-Sub Proj
|
Pubs
|
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
login
to make corrections and additions.
-
-
Assi HA, Hornbacker K, Shaheen S, Wittenberg T, Silberman R, Kunz PL. Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors. Pancreas. 2021 07 01; 50(6):890-894. PMID: 34398071
-
Assi HA, Shikdar S, Alhyari L, Aljumaily R. Long-Term Survival With Nanoliposomal Irinotecan in Pancreatic Cancer. Pancreas. 2020 10; 49(9):e95-e96. PMID: 33003100
-
Assi HA, Asch AS, Machiorlatti M, Vesely SK, Ibrahimi S. Development of thrombocytopenia is associated with improved survival in patients treated with immunotherapy. Future Sci OA. 2020 Jun 25; 6(7):FSO581. PMID: 32802390; PMCID: PMC7421541; DOI: 10.2144/fsoa-2020-0021;
-
Assi HA, Mukherjee S, Machiorlatti M, Vesely S, Pareek V, Hatoum H. Predictors of Outcome in Patients With Fibrolamellar Carcinoma: Analysis of the National Cancer Database. Anticancer Res. 2020 Feb; 40(2):847-855. PMID: 32014928
-
Miller NJ, Khaki AR, Diamantopoulos LN, Bilen MA, Santos V, Agarwal N, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Assi H, Gartrell BA, Sankin A, Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Isaacsson Velho P, Hahn N, Liu S, Alonso Buznego L, Duran I, Moses M, Jain J, Murgic J, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Lyman GH, Grivas P. Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. J Urol. 2020 07; 204(1):63-70. PMID: 31971495; PMCID: PMC7289665; DOI: 10.1097/JU.0000000000000761;
-
Assi HA, Padda SK. Latest advances in management of small cell lung cancer and other neuroendocrine tumors of the lung. Cancer Treat Res Commun. 2020 Jan 16; 23:100167. PMID: 32007735
-
Khaki AR, Li A, Diamantopoulos LN, Bilen MA, Santos V, Esther J, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Assi H, Gartrell BA, Sankin A, Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Isaacsson Velho P, Hahn N, Liu S, Alonso Buznego L, Duran I, Moses M, Jain J, Murgic J, Baratam P, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P. Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer. 2020 03 15; 126(6):1208-1216. PMID: 31829450; PMCID: PMC7050422; DOI: 10.1002/cncr.32645;
-
Assi HA, Mukherjee S, Kunz PL, Machiorlatti M, Vesely S, Pareek V, Hatoum H. Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database. Oncologist. 2020 02; 25(2):e276-e283. PMID: 32043766; PMCID: PMC7011621; DOI: 10.1634/theoncologist.2019-0466;
-
Assi HA, Patel R, Mehdi S. Neuroendocrine carcinoma of the larynx with metastasis to the eyelid. J Community Support Oncol. 2015 Oct; 13(10):378-80. PMID: 26862914
Showing 10 of 18 results.
Show More
-
Kabbach G, Assi HA, Bolotin G, Schuster M, Lee HJ, Tadros M. Hepatobiliary Tumors: Update on Diagnosis and Management. J Clin Transl Hepatol. 2015 Sep 28; 3(3):169-81. PMID: 26623263; PMCID: PMC4663198; DOI: 10.14218/JCTH.2015.00012;
-
El Saghir NS, Zgheib NK, Assi HA, Khoury KE, Bidet Y, Jaber SM, Charara RN, Farhat RA, Kreidieh FY, Decousus S, Romero P, Nemer GM, Salem Z, Shamseddine A, Tfayli A, Abbas J, Jamali F, Seoud M, Armstrong DK, Bignon YJ, Uhrhammer N. BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer. Oncologist. 2015 Apr; 20(4):357-64. PMID: 25777348; PMCID: PMC4391767; DOI: 10.1634/theoncologist.2014-0364;
-
El Saghir NS, Assi HA, Jaber SM, Khoury KE, Nachef Z, Mikdashi HF, El-Asmar NS, Eid TA. Outcome of Breast Cancer Patients Treated outside of Clinical Trials. J Cancer. 2014; 5(6):491-8. PMID: 24959302; PMCID: PMC4066361; DOI: 10.7150/jca.9216;
-
El Saghir NS, Assi HA, Khoury KE, El Zawawy AM, Abbas JA, Eid TA. Re: Tumor boards and the quality of cancer care. J Natl Cancer Inst. 2013 Dec 04; 105(23):1839. PMID: 24187009
-
-
Assi HA, Ayoub ZA, Jaber SM, Sibai HA, El Saghir NS. Management of Paclitaxel-induced hand-foot syndrome. Breast Care (Basel). 2013 Jun; 8(3):215-7. PMID: 24415973; PMCID: PMC3728628; DOI: 10.1159/000352097;
-
El Saghir NS, Assi HA, Pyle D. ASCO's International programs and how you can become involved. Am Soc Clin Oncol Educ Book. 2013; 405-10. PMID: 23714561
-
Sharara AI, Ramia S, Ramlawi F, Farhat B, Bahlawan M, Farhat U, Alameddine M, Nour E, Sayegh R, Yaghi C, Assi H, Ferzli A, Shatila R. Prevalence of restriction fragment length polymorphism patterns of hepatitis B virus compatible with genotype D in Lebanon. Eur J Clin Microbiol Infect Dis. 2004 Nov; 23(11):861-3. PMID: 15480884
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.
| Year | Publications |
|---|
| 2004 | 1 |
| 2013 | 4 |
| 2014 | 1 |
| 2015 | 3 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 1 |
| 2022 | 1 |
2020 University of Oklahoma Health Sciences Center:
Outstanding Fellow in Hematology and Oncology Award
2020 University of Oklahoma Graduate College:
Alpha Epsilon Lambda (AEL) National Honor Society
2019 University of Oklahoma College of Medicine:
Alpha Omega Alpha (AOA) Honor Medical Society
2018 American Society of Hematology:
Abstract Achievement Award